EUVIMEDEUVIMED entdecken
Crossref

Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS ≤ 3 MRI

Yujia Li, Jian Li, Jinhui Yang, Ling Xiao, Ming Zhou, Yi Cai, Axel Rominger, Kuangyu Shi, Robert Seifert, Xiaomei Gao, Yongxiang Tang, Shuo Hu iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-024-06949-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Yujia Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Positron Emission Tomography Computed Tomography, Magnetic Resonance Imaging. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Innovation Program of Hunan Province, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The diagnostic evaluation of men with suspected prostate cancer (PCa) yet inconclusive MRI (PI-RADS ≤ 3) presents a common clinical challenge. [68Ga]Ga-labelled prostate-specific membrane antigen ([68Ga]Ga-PSMA) positron emission tomography/computed tomography (PET/CT) has shown promise in identifying clinically significant PCa (csPCa). We aim to establish a diagnostic model incorporating PSMA-PET to enhance the diagnostic process of csPCa in PI-RADS ≤ 3 men. MATERIALS AND METHODS: This study retrospective included 151 men with clinical suspicion of PCa and PI-RADS ≤ 3 MRI. All men underwent [68Ga]Ga-PSMA PET/CT scans and ultrasound/MRI/PET fusion-guided biopsies. csPCa was defined as Grade Group ≥ 2. PRIMARY-scores from PSMA-PET scans were evaluated. A diagnostic model incorporating PSMA-PET and prostate-specific antigen (PSA)-derived parameters was developed. The discriminative performance and clinical utility were compared with conventional methods. Internal validation was conducted using a fivefold cross-validation with 1000 iterations. RESULTS: In this PI-RADS ≤ 3 cohort, areas-under-the-curve (AUCs) for detecting csPCa were 0.796 (95%CI, 0.738-0.853), 0.851 (95%CI, 0.783-0.918) and 0.806 (95%CI, 0.742-0.870) for PRIMARY-score, SUVmax and routine clinical PSMA-PET assessment, respectively. The diagnostic model comprising PRIMARY-score, SUVmax and serum free PSA/total PSA (fPSA/tPSA) achieved a significantly higher AUC of 0.906 (95%CI, 0.851-0.961) compared to strategies based on PRIMARY-score or SUVmax (P < 0.05) and markedly superior to conventional strategies typically based on PSA density (P < 0.001). The average fivefold cross-validated AUC with 1000 iterations was 0.878 (95%CI, 0.820-0.954). Theoretically, using a threshold of 21.6%, the model could have prevented 78% of unnecessary biopsies while missing only 7.8% of csPCa cases in this cohort. CONCLUSIONS: A novel diagnostic model incorporating PSMA-PET derived metrics-PRIMARY-score and SUVmax-along with serum fPSA/tPSA, has been developed and validated. The integrated model may assist clinical decision-making with enhanced diagnostic accuracy over the individual conventional metrics. It has great potential to reduce unnecessary biopsies for men with PI-RADS ≤ 3 MRI results and warrants further prospective and external evaluations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenPositron Emission Tomography Computed TomographyMagnetic Resonance ImagingGlutamate Carboxypeptidase IIAntigens, SurfaceEdetic AcidUnnecessary ProceduresHumansMaleAgedRetrospective StudiesMiddle AgedGallium RadioisotopesGallium Isotopes

Stichwörter der Autor:innen

MpMRIPETPI-RADSPRIMARY-scorePSMAProstate cancer

Substanzen

Prostate-Specific AntigenGlutamate Carboxypeptidase IIAntigens, SurfaceGallium RadioisotopesFOLH1 protein, humanEdetic Acidgallium 68 PSMA-11Gallium Isotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • National Clinical Research Center for Geriatric Disorders (XIANGYA), Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.
  • Department of Informatics, Technische Universität München, Munich, Germany.
  • Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China. lswindy_2012@163.com.

ORCID-Profile: Shuo Hu

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Innovation Program of Hunan Province
  • Natural Science Foundation of Hunan Province
  • Key Program of Ministray of Industry and Information Technology of China
  • China Postdoctoral Science Foundation
  • Hunan Provincial Science Found for Distinguished Younger Scholars
  • Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases (XIANGYA)
  • Innovative Construction Foundation of Hunan Province

Zitieren

APA

Li, Y., Li, J., Yang, J., Xiao, L., Zhou, M., Cai, Y., Rominger, A., Shi, K., Seifert, R., Gao, X., Tang, Y., & Hu, S. (2025). Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS ≤ 3 MRI. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06949-7

Vancouver

Li Y, Li J, Yang J, Xiao L, Zhou M, Cai Y, et al. Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS ≤ 3 MRI. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-06949-7

BibTeX
@article{Li2025,
  author = {Li, Yujia and Li, Jian and Yang, Jinhui and Xiao, Ling and Zhou, Ming and Cai, Yi and Rominger, Axel and Shi, Kuangyu and Seifert, Robert and Gao, Xiaomei and Tang, Yongxiang and Hu, Shuo},
  title = {Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS ≤ 3 MRI},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-024-06949-7}
}
Kostenlos starten →